News
-
Lightlake Therapeutics, which is developing naloxone nasal sprays for several eating disorders, has announced the appointment of former FDA Commissioner David Kessler as a strategic advisor. Kessler is the author of The End of Overeating:… Read more . . .
-
Acton Pharmaceuticals has announced plans to launch its Aerospan flunisolide HFA metered dose inhaler in early 2013 after having received FDA approval for the MDI. The product is approved for for the maintenance treatment of… Read more . . .
-
Belgian biopharmaceutical company Ablynx has announced positive results from a Phase 1 of its ALX-0171 inhaled Nanobody for the treatment of respiratory syncytial virus (RSV) infections. According to the company, the study demonstrated the safety… Read more . . .
-
In order to meet rising demand for its GMP nasal spray testing services, Melbourn Scientific has dedicated a laboratory to analysis of droplet size, particle characterization, spray pattern, plume geometry, and device performance testing. The… Read more . . .
-
OINDP testing specialist Proveris Scientific UK Limited, a wholly owned subsidiary of Proveris Scientific Corporation, is expanding its operations to support increasing business in Asia and Europe. In addition to hiring a new field service… Read more . . .
-
The FDA has approved InnoPharma’s ANDA for acetylcysteine solution. The New Jersey company has a deal with Fresenius Kabi USA to market acetylcysteine solution in the US, where there has been a shortage of the… Read more . . .
-
Dutch biotech company Mucosis B.V. has promoted Thomas Johnston, the company’s Chief Business Officer since May 2011, as CEO, replacing Govert Schouten. Prior to joining Mucosis, which is developing intranasal vaccines based on its Mimopath… Read more . . .
-
Boehringer Ingelheim has launched the Combivent Respimat ipratropium bromide/albuterol soft mist inhaler for the treatment of COPD in the United States. The Combivent Respimat includes enough doses for 30 days, compared to the Combivent MDI,… Read more . . .
-
Cystic Fibrosis Foundation Therapeutics (CFFT) will provide up to $1.4 million to Pulmatrix to support Phase 1b trials of Pulmatrix’s lead candidate, PUR118, for the treatment of CF. The collaboration between the nonprofit affiliate of… Read more . . .
-
Pearl Therapeutics says that it has completed a Phase 2b dose-ranging study of its PT001 glycopyrrolate (GP) metered dose inhaler in patients with moderate-to-severe COPD. The randomized, double-blind study included 6 doses from 18 µg… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland